Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Pregnancy Outcome in Patients With Neuromyelitis Optica Spectrum Disorder Treated With Rituximab: A Case-Series Study Publisher



Ahadi MS1 ; Sahraian MA1 ; Shaygannejad V2 ; Anjidani N3 ; Nejad SEM4 ; Moghadam NB5 ; Ayromlou H6 ; Pour GAY7 ; Yazdanbakhsh S1 ; Jafari M8 ; Moghadasi AN1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
  3. 3. Medical Department, Orchid Pharmed Company, Tehran, Iran
  4. 4. Department of Neurology, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
  5. 5. Department of Neurology, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  6. 6. Department of Neurology, Faculty of Medicine, Tabriz University of Medical Sciences, Iran
  7. 7. Department of Neurology, Shiraz University of Medical Sciences, Shiraz, Iran
  8. 8. Imam Khomeini Hospital complex, Tehran University of Medical Sciences, Tehran, Iran

Source: Caspian Journal of Internal Medicine Published:2021


Abstract

Background: Neuromyelitis optica spectrum disorder (NMOSD) is a neuroinflammatory disorder with a tendency to affect the spinal cord and optic nerves. As NMOSDs have a predilection for women of reproductive age and adopt an aggressive course during pregnancy, appropriate treatment strategies before conception and during pregnancy should be well-considered. Case Presentation: In this report, the pregnancy outcome of eight pregnancies following rituximab treatment was assessed, which led to 50% live births with mean birth weight of 2777.50 (SD: 545.92) grams. Two patients had abortions due to doctor’s recommendation. One pregnancy led to intrauterine fetal death (IUFD) due to nuchal cord. No spontaneous abortions were encountered. Two patients received rituximab during pregnancy. No major malformations or serious neonatal infections were encountered. Conclusion: Rituximab should be administered by caution in NMOSD patients who want to be pregnant and the probable adverse effects of the drug should be discussed by patients. © The Author(s)
Related Docs
1. Pregnancy Outcome in Patients With Multiple Sclerosis Treated With Rituximab: A Case-Series Study, Multiple Sclerosis and Related Disorders (2021)
2. Microorganisms in Pathogenesis and Management of Neuromyelitis Optica Spectrum Disorder, Role of Microorganisms in Pathogenesis and Management of Autoimmune Diseases: Volume II: Kidney# Central Nervous System# Eye# Blood# Blood Vessels and Bowel (2023)
3. Adverse Drug Reactions of Rituximab in Patients Suffering From Autoimmune Neurological Diseases, DARU# Journal of Pharmaceutical Sciences (2022)
4. Exploring the Association of Reproductive History With the Development and Course of Neuromyelitis Optica Spectrum Disorder, Clinical Neurology and Neurosurgery (2022)
5. Evaluation of Covid-19 Infection in Patients With Neuromyelitis Optica Spectrum Disorder (Nmosd): A Report From Iran, Multiple Sclerosis and Related Disorders (2020)
Experts (# of related papers)
View all Related Experts
Mohammad Ali Sahraian (3)
Amirreza Azimi (2)